The capsule of the fungal pathogen Cryptococcus neoformans has been studied extensively
in recent decades and a large body of information is now available to the scientific …

Many biological recognition processes involve the binding and clustering of ligand− receptor
complexes and concomitant signal transduction events. Such interactions have recently …

The murine monoclonal antibody (MAb) 18B7 [immunoglobulin G1 (κ)] is in preclinical
development for treatment of Cryptococcus neoformans infections. In anticipation of its use …

Cryptococcus neoformans is an opportunistic pathogenic yeast that causes serious
infections, most commonly of the central nervous system (CNS). C. neoformans is mainly …

Fifty years after the introduction of the first effective antimicrobial agents against
Mycobacterium tuberculosis, this pathogen continues to be a tremendous public health …

Nations' ongoing struggles with a number of novel and reemerging infectious diseases,
including the ongoing global health issue, the SARS-Co-V2 (severe acute respiratory …

For many pathogens the role of antibody-mediated immunity (AMI) is poorly understood, in
part because of the limited tools available to establish antibody efficacy. AMI is classically …

One of the most troublesome medical problems today is infection of prosthetic devices with
organisms that form polysaccharide biofilms. This combined with increasing antimicrobial …

IgM and IgA to the Cryptococcus neoformans capsular glucuronoxylomannan (GXM)
promote complement-independent phagocytosis by macrophages with efficiency …

The most distinctive feature of the human pathogenic fungus is a polysaccharide capsule
that is essential for virulence and is composed primarily of glucuronoxylomannan (GXM) and …